Johnson & Johnson to Acquire Firefly Bio Inc. to Expand Oncology Pipeline With Novel Degrader Antibody Conjugate Platform
June 09, 2026
June 09, 2026
RARITAN, New Jersey, June 9 -- Johnson and Johnson Innovative Medicine issued the following news release on June 8, 2028:
* * *
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
* Expands the Company's expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers
* Acquisition adds a proprietary degrader antibody conjugate platform designed to overcom . . .
* * *
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
* Expands the Company's expertise in targeting pan-KRAS and other drivers of hard-to-treat cancers
* Acquisition adds a proprietary degrader antibody conjugate platform designed to overcom . . .